Alexion stalks rare disease drug from Stealth with $30m opt-in dealAlexion has taken an option on a rare disease drug from Stealth Therapeutics in late-stage development, bolstering its Share XAlexion stalks rare disease drug from Stealth with $30m opt-in dealhttps://pharmaphorum.com/news/alexion-stalks-rare-disease-drug-from-stealth-with-30m-opt-in-deal/
UCB sets sights on rare diseases giant Alexion with Ra Pharma acquisitionUCB is to buy US biotech Ra Pharma in a deal worth around $2.1 billion, adding a late-stage Share XUCB sets sights on rare diseases giant Alexion with Ra Pharma acquisitionhttps://pharmaphorum.com/news/ucb-takes-on-rare-diseases-giant-alexion-with-ra-pharma-acquisition/
Roche preps filings for satralizumab in rare disease NMOSDRoche is two for two in its phase 3 trials programme for satralizumab in the rare disease neuromyelitis Share XRoche preps filings for satralizumab in rare disease NMOSDhttps://pharmaphorum.com/news/roche-preps-filings-for-satralizumab-in-rare-disease-nmosd/
Alexion’s biosimilar-blocking EU patent play for Soliris failsThe European Patent Office has blocked an attempt by Alexion to extend the patent protection for its blockbuster Share XAlexion’s biosimilar-blocking EU patent play for Soliris failshttps://pharmaphorum.com/news/alexions-biosimilar-blocking-eu-patent-play-for-soliris-fails/
Alexion’s Soliris approved in new optic nerve disease use in EuropeAlexion’s rare disease drug Soliris has been approved in a new use in Europe, to tackle a disorder Share XAlexion’s Soliris approved in new optic nerve disease use in Europehttps://pharmaphorum.com/news/alexions-soliris-approved-in-new-optic-nerve-disease-use-in-europe/
Alexion’s Soliris follow-up Ultomiris snares EU approvalAlexion has the EU approval it needed for Ultomiris, a follow-up to its rare disease therapy Soliris that Share XAlexion’s Soliris follow-up Ultomiris snares EU approvalhttps://pharmaphorum.com/news/alexions-soliris-follow-up-ultomiris-snares-eu-approval/
R&D Roundup: Pharma gets in on the biotech boomSome good news for the UK industry in turbulent times is always welcome, and several announcement this month Share XR&D Roundup: Pharma gets in on the biotech boomhttps://pharmaphorum.com/r-d/views-analysis-r-d/rd-roundup-pharma-gets-in-on-the-biotech-boom/
A lifeline for rare disease patientsFor more than 25 years Alexion has been blazing a trail in rare diseases, bringing a series of Share XA lifeline for rare disease patientshttps://deep-dive.pharmaphorum.com/magazine/pharma-research-rare-diseases/alexion-sean-richardson-charles-de-wet/
Alexion signs R&D deals with two Nordic biotechsAlexion has signed a deal with two Nordic biotechs to bolster its pipeline of potential rare disease drugs. Share XAlexion signs R&D deals with two Nordic biotechshttps://pharmaphorum.com/news/alexion-signs-rd-deals-with-two-nordic-biotechs/
